COMPASS Pathways plc (NASDAQ:CMPS) Given Consensus Recommendation of “Buy” by Brokerages

COMPASS Pathways plc (NASDAQ:CMPS) has received an average recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $20.20.

A number of brokerages have issued reports on CMPS. Canaccord Genuity Group reduced their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Cantor Fitzgerald upgraded COMPASS Pathways to a “strong-buy” rating in a research report on Tuesday, May 13th. Stifel Nicolaus began coverage on COMPASS Pathways in a research report on Thursday, February 27th. They set a “buy” rating and a $11.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of COMPASS Pathways in a research report on Monday, May 12th.

Institutional Investors Weigh In On COMPASS Pathways

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cerity Partners LLC bought a new stake in COMPASS Pathways in the first quarter worth about $29,000. GAMMA Investing LLC raised its position in COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock worth $30,000 after acquiring an additional 5,003 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in COMPASS Pathways in the fourth quarter worth about $41,000. Wealthfront Advisers LLC bought a new stake in COMPASS Pathways in the fourth quarter worth about $43,000. Finally, Flagship Harbor Advisors LLC bought a new stake in COMPASS Pathways in the fourth quarter worth about $43,000. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Price Performance

Shares of CMPS opened at $3.98 on Monday. The company has a market cap of $369.54 million, a P/E ratio of -1.81 and a beta of 2.27. The stock has a fifty day moving average price of $3.35 and a 200 day moving average price of $3.93. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a 12 month low of $2.49 and a 12 month high of $8.54.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03. On average, research analysts forecast that COMPASS Pathways will post -2.33 earnings per share for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.